NVO - Novo Nordisk A/S

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Novo Nordisk reduces its U.S. sales team for obesity and diabetes education: Reuters
• Roche deal to buy 89bio boosts MASH space
• Novo Nordisk pops after Ozempic beats Lilly’s older drug in heart risk study
• Novo Nordisk’s Wegovy pill delivers 16.6% weight loss in people with obesity
• FDA targets drug marketing, advertising with slew of warning letters
• Lilly obesity pill more effective to Novo's oral semaglutide in diabetes trial
• Eli Lilly, Novo Nordisk rebuked by FDA for claims made in Oprah weight loss video
• Novo Nordisk to seek U.S. nod for high-dose Wegovy: report
• SA Asks: Which biotechs could be acquired by year's end?
• Novo Nordisk directs employees to resume full-time office work
• Cigna cites flat obesity drug coverage rates among employers
• Trump administration moves to regulate pharmaceutical ads on TV and social media
• Novo Nordisk to cut 9,000 jobs in $1.25 billion overhaul, trims 2025 profit outlook
• Novo Nordisk raised to Outperform at Bernstein on obesity drug led growth
• GLP-1s are cost-effective, drug pricing watchdog ICER says
• FDA targets illegal imported GLP-1 ingredients
• Novo's Wegovy beats Lilly’s Zepbound in real-world study for heart diseases
• Notable analyst calls this week: AMD, Eli Lilly and Constellation Brands among top picks
• Denmark cuts growth forecast amid troubles for Novo Nordisk
• Teva gets FDA nod for generic version of Novo's weight loss drug